Shared on31 Jul 25Fair value Decreased 11%
Novo Nordisk's consensus analyst price target saw a minor decrease, with revenue growth and future P/E forecasts remaining essentially stable, resulting in a slight downward revision of fair value to DKK553.19. What's in the News Maziar Mike Doustdar has been appointed CEO, succeeding Lars Fruergaard Jørgensen, who steps down amid share price and market challenges.
Shared on23 Apr 25Fair value Decreased 0.93%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Decreased 4.91%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Decreased 1.77%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 2.02%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Increased 0.35%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Decreased 0.51%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on11 Mar 25Fair value Increased 25%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.